Known targets — ChEMBL curated mechanism
ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3CHRM1CHRM2CHRM3CHRM4ESR1ESR2GABRA1GABRB1GABRG2GBA1HRH1HTR1DHTR2AOPRD1OPRK1OPRM1SLC6A2SLC6A3TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8rplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Cadaverine Tartrate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A1 | P30531 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | SLC6A11 | P48066 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | SLC6A13 | Q9NSD5 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | CPN1 | P15169 | 2/20 | 0.39 |
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cadaverine Tartrate SCHEMBL8198834 | 1.00 | SLC6A1 (0.47) | SLC6A1SMN1; SMN2SLC6A11TSHRLMNA | |
| Cadaverine Tartrate SCHEMBL6970212 | 1.00 | SLC6A1 (0.47) | SLC6A1SMN1; SMN2SLC6A11TSHRLMNA | |
| Tartaric Acid SCHEMBL29880655 | 1.00 | SLC6A1 (0.47) | SLC6A1SMN1; SMN2SLC6A11TSHRLMNA | |
| SCHEMBL132089 | 0.89 | SLC6A1 (0.53) | SLC6A1SMN1; SMN2SLC6A11TSHRLMNA | |
| SCHEMBL132090 | 0.89 | SLC6A1 (0.53) | SLC6A1SMN1; SMN2SLC6A11TSHRLMNA | |
| SCHEMBL134525 | 0.89 | SLC6A1 (0.53) | SLC6A1SMN1; SMN2SLC6A11TSHRLMNA | |
| Hydrochloric Acid SCHEMBL205293 | 0.88 | SLC6A1 (0.52) | SLC6A1SMN1; SMN2SLC6A11TSHRLMNA | |
| Hydrochloric Acid SCHEMBL5215224 | 0.88 | SLC6A1 (0.52) | SLC6A1SMN1; SMN2SLC6A11TSHRLMNA | |
| Hydrochloric Acid SCHEMBL22444028 | 0.88 | SLC6A1 (0.52) | SLC6A1SMN1; SMN2SLC6A11TSHRLMNA | |
| SCHEMBL14525966 | 0.85 | ALDH1A1 (0.50) | SLC6A1SMN1; SMN2SLC6A11TSHRLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080182874-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2008-07-31 | — | — | US | disclosed |
| US-6569849-B1 | N-Substituted azaheterocyclic compounds | NOVO NORDISK A/S (DK) | 2003-05-27 | — | — | US | disclosed |
| EP-0934313-B1 | N-SUBSTITUTED AZAHETEROCYCLIC COMPOUNDS | NOVO NORDISK AS (DK) | 2003-05-14 | — | — | EP | disclosed |
| US-20020151539-A1 | Novel heterocyclic compounds | JORGENSEN TINE KROGH (DK) | 2002-10-17 | — | — | US | disclosed |
| EP-0851865-B1 | 12H-Dibenzo[d,g][1,3]dioxocine derivatives | NOVO NORDISK AS (DK) | 2002-07-17 | — | — | EP | disclosed |
| US-6391890-B1 | ANALGESICS, ANTIINFLAMMATORY AGENTS, NON-INSULIN DEPENDENT DIABETES | NOVO NORDISK A/S (DK) | 2002-05-21 | — | — | US | disclosed |
| EP-0869954-B1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF NEUROGENIC INFLAMMATION | NOVO NORDISK AS (DK) | 2001-09-19 | — | — | EP | disclosed |
| EP-0820450-B1 | N-substituted azaheterocyclic carboxylic acids and alkylesters thereof | NOVO NORDISK AS (DK) | 2001-09-12 | — | — | EP | disclosed |
| US-6060468-A | ANTIINFLAMMATORY AGENTS | NOVO NORDISK A/S (DK) | 2000-05-09 | — | — | US | disclosed |
| US-6054458-A | Heterocyclic compounds | NOVONORDISKALS (DK) | 2000-04-25 | — | — | US | disclosed |
| EP-0738262-A1 | NOVEL HETEROCYCLIC COMPOUNDS | NOVO NORDISK A/S (DK) | 1996-10-23 | — | — | EP | disclosed |
| WO-1996031499-A1 | NOVEL HETEROCYCLIC COMPOUNDS | NOVO NORDISK A/S (DK) | 1996-10-10 | — | — | WO | disclosed |
| WO-1996031469-A1 | N-SUBSTITUTED AZAHETEROCYCLIC CARBOXYLIC ACIDS AND ESTERS THEREOF | NOVO NORDISK A/S (DK) | 1996-10-10 | — | — | WO | disclosed |
| WO-1996031497-A1 | NOVEL HETEROCYCLIC COMPOUNDS | NOVO NORDISK A/S (DK) | 1996-10-10 | — | — | WO | disclosed |
| WO-1996031471-A1 | NOVEL METHOD | NOVO NORDISK A/S (DK) | 1996-10-10 | — | — | WO | disclosed |
| EP-0705246-A1 | N-SUBSTITUTED AZAHETEROCYCLIC CARBOXYLIC ACIDS AND ESTERS THEREOF | NOVO NORDISK A/S (DK) | 1996-04-10 | — | — | EP | disclosed |
| EP-0705248-A1 | N-SUBSTITUTED AZAHETEROCYCLIC CARBOXYLIC ACIDS AND ESTERS THEREOF | NOVO NORDISK A/S (DK) | 1996-04-10 | — | — | EP | disclosed |
| WO-1995018793-A1 | NOVEL HETEROCYCLIC COMPOUNDS | NOVO NORDISK A/S (DK) | 1995-07-13 | — | — | WO | disclosed |
| WO-1995000486-A1 | N-SUBSTITUTED AZAHETEROCYCLIC CARBOXYLIC ACIDS AND ESTERS THEREOF | NOVO NORDISK A/S (DK) | 1995-01-05 | — | — | WO | disclosed |
| WO-1995000483-A1 | N-SUBSTITUTED AZAHETEROCYCLIC CARBOXYLIC ACIDS AND ESTERS THEREOF | NOVO NORDISK A/S (DK) | 1995-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080182874-A1 | Novel Compounds | REN, F12, GPR119 | SLC6A1 928/4885SMN1; SMN2 812/4885SLC6A11 767/4885 |
| US-20020151539-A1 | Novel heterocyclic compounds | IAPP, GPR119, NPY1R | SLC6A1 4566/4885SMN1; SMN2 522/4885SLC6A11 4429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.